Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term ‘Adrenal Franchise’. Alkindi® is currently being rolled out through key European markets and has been submitted to the FDA for approval, with a PDUFA date set at 29 September 2020. Meanwhile, Diurnal has signed an exclusive US commercial deal with Eton Pharmaceuticals, a specialty pharma company focused on hospital and paediatric products. This, together with the recent Placing, has strengthened the balance sheet.
Download the full report
If you'd like to be introduced to the team at Diurnal Group Plc, get in touch.Request a meeting